| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Rain Oncology, Inc. (NASDAQ:RAIN) ("Rain") confirmed that it has received an unsolicited proposal from Tang Capital, LP on behalf of Concentra Biosciences LLC to acquire all outstanding shares of common stock of Rain for $1.25 per share in cash, plus a contingent value right ("CVR") representing the right to receive 80% of the net proceeds payable from any license or disposition of Rain's programs.
Rain's Board of Directors and management team regularly review opportunities to generate stockholder value and are committed to acting in the best interests of all stockholders.
Consistent with its fiduciary duties, Rain's Board of Directors, in consultation with its independent financial and legal advisors, will carefully review and evaluate the proposal from Concentra Biosciences.
Rain's stockholders are advised to take no action at this time.
Posted In: RAIN
